Meeting
2024 ASCO Annual Meeting
Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics.
Authors
Rithika Rajendran
The Edward P. Evans Foundation Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC
Rithika Rajendran , Coen Johannes Gerardus Lap , Fayez Estephan , Shanshan Liu , Ramesh Subrahmanyam , Guoqing Diao , Victor Nava , Maneesh Rajiv Jain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Biologic Correlates
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5019)
DOI
10.1200/JCO.2024.42.16_suppl.5019
Abstract #
5019
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The association of age with breast cancer mortality within four race/ethnicities for the triple negative and HER2-overexpressing subtypes.
First Author: Carol Parise
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2021 ASCO Annual Meeting
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.
First Author: Tariqa Ackbarali
Poster
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
First Author: Arielle Lutterman Heeke